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Abstract The present study was designed to explore the
ability of polymeric nanoparticles to restore drug sensitivity to
P-glycoprotein over-expressing cancer cells. A multidrug-
resistant cell line 2780 AD and its sensitive parent cell line
A2780 were studied in cell culture and as a xenografted
tumour model. Paclitaxel was incorporated in poly(lactide-co-
glycolide) nanoparticles of average diameter 125 nm stabi-
lised by a positively charged surfactant. The nanoparticulate
formulation was shown to be about sevenfold more potent
than free paclitaxel against cell line A2780 and the poly
(lactic-co-glycolic acid) (PLGA) nanoparticles alone were
nontoxic to the cells at the concentrations required to deliver
the drug. Whilst the oral formulation of paclitaxel was not as
potent as the free drug in the A2780 xenografts, it showed
significant activity against 2780 AD tumours, which are
resistant to the maximum tolerated intravenous dose of
paclitaxel. The efficacy of orally delivered paclitaxel in this
drug-resistant model supports the concept of exploring
nanoparticles for improved drug delivery.
Keywords P-glycoprotein . EPR effect . Nanoparticles .
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1 Introduction
Drug resistance is a common cause of treatment failure in
anticancer therapy. One mechanism of drug resistance
identified in studies with cell lines is through expression
of drug transporters that pump the drug out of the cells.
Paclitaxel is one of the most effective drugs against cancer.
However, its clinical utility is limited due to unfavourable
solubility in water and poor permeability across the
biological barriers. Furthermore, it is extensively pumped
out by the P-glycoprotein (Pgp; Roy and Horwitz 1985).
Due to these reasons, the drug shows poor bioavailability
when administered orally. Therefore, it is typically admin-
istered intravenously in a mixture of cremophor EL™ and
alcohol, but this vehicle can cause anaphylactoid reactions
(Dye and Watkins 1980).
Novel drug delivery strategies are being explored for
delivery of paclitaxel. Small particles can improve the oral
bioavailability of medicinal compounds (Florence 1997;
Sakuma et al. 2001). The particles are believed to be
delivered to the systemic circulation through the lymphatic
system (Sakuma et al. 2001; Eldridge et al. 1990). Due to
their profoundly different pharmacokinetics and cellular
disposition, they may be considered as implanted mobile
depots of drugs and offer many unexplored benefits.
A2780 is a human ovarian carcinoma cell line that is
sensitive to doxorubicin and many other cytotoxic drugs
including paclitaxel. 2780 AD is a multidrug-resistant variant
of A2780 that was developed by repeated exposure to
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doxorubicin. The main mechanism of resistance is over-
expression of the Pgp, and this resistance is shared towards
other anticancer drugs that are substrates (Dantzig et al. 1996).
2780 AD is about 2,000-fold resistant to paclitaxel compared
to the parental A2780 cell line. When grown as xenografts in
athymic nude mice, A2780 shows a significant growth delay
when the mice are treated with paclitaxel. By contrast,
tumours of 2780 AD are resistant to the maximum tolerated
dose of paclitaxel. However, 2780 AD can be sensitised to
paclitaxel by treatment of the mice with an inhibitor of the
drug efflux pump (Mistry et al. 2001).
Liposomes have been shown to increase the accumula-
tion of doxorubicin in MDR Chinese hamster LZ, human
breast cancer MCF-7/ADR, and the ovarian carcinoma
SKVLB cell line as a result of changes in the intracellular
vesicular transport (Thierry et al. 1993). In a study with
drug-resistant cell lines, it has been shown that doxorubicin
encapsulated in polymer–lipid nanoparticles was accumu-
lated within the cell to a higher degree compared to free
doxorubicin (Wong et al. 2006).
Lipid partitioning of the substrate in the membrane
structure has been postulated as essential for efflux, and
the lipid type can affect the interaction with the substrate
(Romsicki and Sharom 1999). Liposomes increased vin-
blastine accumulation in resistant human lymphoblastic
leukemic cell CEM/VLB100 even when the drug was co-
administered in free form rather than incorporated within
the liposomes, probably due to amalgamation of lipidic
components into cell membrane lipids and subsequent
alteration in membrane fluidity (Warren et al. 1992).
Pluronic block copolymers have been shown to sensitise
MDR cell lines to cytotoxics (Kabanov et al. 2002). A
micellar formulation of pluronic doxorubicin conjugate
SP1049C is presently undergoing Phase II clinical trials
for Pgp-targeted therapy (Valle et al. 2010).
Polymeric nanoparticles have been documented to
reverse drug resistance in cancer cell lines based on the
hypothesis of transport through endocytic pathways (Cuvier
et al. 1992). However, local high concentrations of drug
released from polymeric nanoparticles adsorbed on to
resistant P388/ADR cell surface have also been proposed
to reverse resistance (de Verdière et al. 1997). A coculture
of these cells with macrophages showed beneficial effects
especially when combined with cyclosporin A, which is an
inhibitor of the Pgp efflux transporters (Soma et al. 1999).
The cytotoxic and the inhibitor have been encapsulated into
a single nanoparticulate carrier system (Emilienne Soma
et al. 2000). Curiously, it was believed that nanoparticles of
185 nm cannot be of utility in solid tumours implanted
subcutaneously in animals, because they would not diffuse
out of the vascular endothelium and migrate to the cancer
cells (de Verdière et al. 1997).
We have reported development of polymeric nano-
particles incorporating paclitaxel which showed activity in
a chemically induced breast tumour model in rats when
administered orally (Bhardwaj et al. 2009). In this study, we
have examined the ability of these orally delivered nano-
particles to inhibit the growth of human ovarian tumours
grown subcutaneously in athymic nude mice.
2 Material and methods
2.1 Material
Paclitaxel was obtained from Samyang Genex (as Genexol®)
(Seoul, South Korea) and Sigma-Aldrich (St. Louis, MO, USA).
Didodecyldimethylammonium bromide (DMAB) was pur-
chased from Fluka Buchs SG, Switzerland). Poly(lactic-co-
glycolic acid) (PLGA) 50:50 block copolymer (RG 503H,
molecular weight 35–40 kDa) was procured from Boehringer
Ingelheim KG (Ingelheim, Germany). All other chemicals were
purchased from Sigma-Aldrich and were used as obtained.
2.2 Preparation of paclitaxel-loaded nanoparticles
Drug-loaded nanoparticles were prepared with initial drug
loading of 5% (w/w of PLGA) paclitaxel. In brief, 2.5 mg
paclitaxel was dissolved in 5 ml ethyl acetate and 50 mg
PLGA was added to this solution and stirred for 2 h.
This solution was poured with stirring in 5 ml of aqueous
1.0% w/v DMAB solution. The primary emulsion so obtained
was homogenised for 5 min by a shaft-type tissue homogeniser
at 15,000 rpm (Polytron 4000, Kinematica, Switzerland).
Finally, this emulsion was diluted six times with water and
stirred at 800 rpm with a magnetic bar for 4–6 h to remove the
ethyl acetate. Nanoparticle suspension obtained was washed
twice by centrifugation to remove the unbound drug and
surfactant. The prepared formulation was characterised for
size, zeta potential and polydispersity index (PDI) using
Zetasizer (Nano-ZS, Malvern, UK). Analysis of paclitaxel
was carried out by high-performance liquid chromatography
(HPLC,Waters, USA) using ultraviolet detection at 227 nm on
a 250×4.6 mm reverse phase C18 (Symmetry or Lichrocart)
column. A mobile phase consisting of methanol, acetonitrile
and 5 mM phosphate buffer (pH 2.5) in the ratio 70.0:2.5:27.5
eluted paclitaxel from a 20 μl injection in 7–8 min when
pumped at 0.7 ml/min.
2.3 Cell culture
The human ovarian carcinoma cells, A2780, and its drug-
resistant variant, 2780 AD, were provided by Dr. T. C.
Hamilton (Fox Chase Center, Philadelphia, PA). The
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2780 AD cells were resistant to both doxorubicin and
paclitaxel (Mistry et al. 2001). They were maintained in
Roswell Park Memorial Institute 1640 (RPMI 1640) medium
containing glutamine (2 mM) and foetal calf serum (10%).
Cells were grown to ~90% confluence in 75 cm2T-flasks.
Culture medium was changed on alternate days, and cells
were cultured at a temperature of ~37°C in an atmosphere of
~85% relative humidity and ~5% CO2.
2.4 Cytotoxicity assay
Drug sensitivity was determined by a tetrazolium dye-based
assay (MTT; Plumb et al. 1989). Cells were seeded at a
density of 2×103 (2780 AD) or 1×103 (A2780) cells/well
in 96-well flat-bottomed plates (Iwaki from Bibby, Bicester,
Oxon) and allowed to attach and grow for 48 h. The cells
were exposed to drug for 24–72 h. Nanoparticles containing
paclitaxel were either prepared under sterile conditions
or filtered through a 0.22-μm filter. Paclitaxel in dimethyl
sulphoxide (DMSO), polymeric nanoparticles, and poly-
meric nanoparticles containing paclitaxel were diluted in
cell culture medium for use. After a defined incubation
time, drug was removed and the cells grown in fresh
medium for 72 h, after which cells were fed with medium
and MTT (50 μl, 5 mg/ml) was added to each well. Plates
were incubated in the dark at 37°C for 4 h, medium was
removed, and MTT formazan crystals were dissolved in
DMSO (200 μl/well). Glycine buffer (25 μl/well, 0.1 M,
pH 10.5) was added to make the contents alkaline, and the
absorbance was measured at 570 nm in a multiwell plate
reader (Emax,Molecular Devices with Softmax Pro analytical
software). A typical dose–response curve consisted of eight
drug concentrations, and four wells were used per drug
concentration. Sensitivity is expressed as the IC50 (mean ±
SEM of three experiments) defined as the concentration of
drug required to reduce the absorbance of the wells to 50%
of that of the control untreated cells.
2.5 Efficacy studies in tumours in vivo
Animal studies were carried out under an appropriate
United Kingdom Home Office Project Licence, and all
work conformed to the UKCCR Guidelines for the welfare
of animals in experimental neoplasia. Monolayer cultures
were harvested with trypsin/ethylenediaminetetraacetic acid
(EDTA) and resuspended in phosphate buffered saline
(PBS). About 107 cells were injected subcutaneously into
the right flank of athymic nude mice (CD1 nu/nu mice from
Charles River). After 7 to 10 days when the mean tumour
diameter was at ≥0.5 cm, animals were randomised in
groups of 6 for experiments (Workman 2010). Mice
received either no treatment, paclitaxel (15 mg/kg body
weight, i.v.) in cremophor EL and ethanol mixture (5%:5%)
diluted in dextrose solution (90%), blank nanoparticles
orally (dose equivalent of drug-loaded) or the drug-loaded
nanoparticulate formulation orally containing paclitaxel
equivalent to 15 mg/kg body weight. Mice were weighed
daily, and tumour volumes were estimated by caliper measure-
ments assuming spherical geometry (volume=d3×π/6).
3 Results
3.1 Preparation of paclitaxel-loaded nanoparticles
Particles prepared with 1% DMAB with an initial load of
5% w/w of paclitaxel relative to the polymer weight had an
average particle size of about 120 nm (Bhardwaj et al.
2009). Particles were positively charged as indicated by
zeta potential values of 50–60 mV. The particle washing did
not appreciably increase the particle size (mean average
particle size 130 nm).
3.2 Cytotoxicity of the nanoparticles
The cytotoxicity of paclitaxel and the drug-loaded nano-
particles is shown in Table 1. A2780 is about 2,000-fold
more sensitive to paclitaxel than the drug-resistant deriva-
tive (IC50 2.26±0.91 nM for A2780 cf. 5240±637 nM for
2780 AD). The blank nanoparticles were relatively nontoxic
to the cells with an IC50 based on the theoretical paclitaxel
load of 1774±129 nM. Formulation of paclitaxel with the
nanoparticles increased the toxicity of the drug to the drug-
sensitive cell line A2780 by about sevenfold (free drug
2.26±0.91 cf. nanoparticle 0.30±0.03 nM). The paclitaxel
sensitivity of the drug-resistant derivative was increased by
prolonged exposure to the drug (Table 1). However, the
nanoparticles themselves were toxic to the cells at the
Table 1 Paclitaxel sensitivity of cell lines A2780 and the drug-
resistant derivative 2780AD to paclitaxel and paclitaxel nanoparticles
IC50 (nM)
A2780 2780 AD
24 h 24 h 72 h
Blank nanoparticles 1,774±129 – 3,175±79
Paclitaxel 2.26±0.91 5,240±637 2,013±73
Paclitaxel nanoparticles 0.30±0.03 1,661±89 903±49
Sensitivity is expressed as the IC50 (mean±SEM of three estimations)
defined as the concentration of drug required to reduce the absorbance
of the wells to 50% of that of the control untreated cells
Polymer nanoparticles for drug-resistant cancer 31
concentrations required to achieve paclitaxel IC50 concen-
tration (3175±79 nM for the blank particles cf the IC50 for
paclitaxel of 2013±73 nM).
3.3 Efficacy of the nanoparticles in human tumour
xenograft models
The effect of paclitaxel and the drug-loaded nanoparticles
on the growth of tumours derived from the drug-sensitive
A2780 cell line is shown in Fig. 1. Paclitaxel treatment
produces a significant growth delay with no apparent toxicity
as measured by changes in body weight. The drug-loaded
nanoparticles when given orally also inhibit the growth of
the tumours, but the growth delay is not as marked as with the
intravenous preparation. Tumours derived from the drug-
resistant variant of A2780 (2780 AD) are resistant to the
maximum tolerated dose of the intravenous paclitaxel
preparation (15 mg/kg×3). However, in this model, treatment
with the paclitaxel-loaded nanoparticles given orally results in
a growth delay comparable to that seen in the drug-sensitive
A2780 model with this formulation. The blank nanoparticles
alone have no effect on tumour growth and are nontoxic
to the mice as measured by effects on the body weight
and behaviour.
4 Discussion
We have shown clearly that the paclitaxel-loaded nano-
particles are able to deliver paclitaxel to the tumour when
given by the oral route. Furthermore, the nanoparticles can
partially circumvent multidrug resistance in vivo. PLGA is
a biodegradable and biocompatible polymer approved by
the US Food & Drug Administration for human use and is a
popular material for preparing nanoparticles for drug
delivery. A nanoparticulate formulation has been shown
to enable oral delivery of otherwise poorly bioavailable
paclitaxel and impart improved efficacy (Bhardwaj et al.
2009). The present study supports and extends these
observations.
The paclitaxel-loaded nanoparticles retained activity in
cell lines in vitro. Interestingly, the formulation was able to
increase the sensitivity of the already relatively sensitive
cell line A2780 by about sevenfold (Table 1). The nano-
particles were nontoxic to the cells at the concentrations
required to deliver sufficient paclitaxel to the cells. For
comparison, the IC50 concentrations of the blank nano-
particles is expressed in paclitaxel equivalents, i.e. the
amount needed to give the required concentration of
paclitaxel. Since the IC50 of the blank particles is about
500-fold greater than the concentration required to deliver
the IC50 concentration of paclitaxel (Table 1), the increased
toxicity of the drug-loaded nanoparticles cannot be explained
by toxicity of the nanoparticle itself. By contrast, the drug-
resistant variant 2780 AD is about 2,000-fold resistant to
paclitaxel, and in order to deliver this concentration of
paclitaxel, the nanoparticles are used at close to their toxic
concentration. Thus we cannot exclude the possibility that
the increased activity in this cell line is due to combined
toxicity of the paclitaxel and the nanoparticles.
The observed IC50 values of the blank nanoparticles in
the drug-resistant cell line raises questions about the
inherent cytotoxicity of the polymeric nanoparticles per
se. One possible explanation is that the particles, merely
with their physical presence beyond a particular threshold,
are interfering with structural integrity dynamics or meta-
bolic process of the cells. An alternate hypothesis could be
that they are making a physical barrier on the surface of
cells that inhibits transport of nutrition across the cells, and
this effect is dependent on the concentration. Clearly, the
washing of the well contents by aspiration of medium is
ineffective in disturbing this association with the cells. The











































Fig. 1 The effect of paclitaxel and paclitaxel nanoparticles on the
growth of tumours of cell line A2780 when grown as xenografts in
mice. Mice were treated once tumours reached a mean diameter of
0.5 cm. Groups of six mice were either untreated (●), given paclitaxel
(dissolved in cremophor EL, ethanol, dextrose) intravenously (▼), or
paclitaxel-loaded nanoparticles orally (■) on days 0, 2, and 4. Tumour
volumes (A) and body weights (B) are expressed relative to that on the
day of treatment (day 0) and results are the mean±SEM of six mice
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with the negatively charged residues at the surface of the
cell membrane. Although we assume that the particles are
internalised, this process is saturable, as indicated by the
concentration results.
In view of the promising activity seen in the cell lines in
vitro, we evaluated the particles in human tumour xeno-
grafts in vivo. Immunodeficient animals have the advantage
that we can study the same human tumour cells that we use
for the in vitro studies in an in vivo model. Tumours
established from the drug-sensitive A2780 cell line show a
marked growth inhibition when treated with the maximum
tolerated dose of paclitaxel (15 mg/kg, i.v.×3; Fig. 1).
Paclitaxel has very limited bioavailability when given by
the oral route. However, although not as effective as the
standard treatment regimen, the orally delivered paclitaxel
nanoparticles showed activity in this model. This result
differs from that of an earlier study in chemically induced
rat tumour model, where nanoparticulate formulation at half
the dose was equivalent to the micellar one (Bhardwaj et al.
2009). The drug-resistant derivative of A2780 (2780 AD)
has the MDR phenotype and is very resistant to the group
of drugs involved (Plumb et al. 1990). Although this is an
in vitro derived drug-resistant cell line, it provides a useful
model to evaluate strategies to circumvent drug resistance
mechanisms. We have shown that sensitivity to paclitaxel
can be increased by treatment with an inhibitor of the drug
efflux pump (Mistry et al. 2001). Tumours derived from
2780 AD are resistant to the maximum tolerated dose of
paclitaxel (Fig. 2). However, these tumours showed a
significant growth delay when mice were treated with the
oral paclitaxel nanoparticles. Furthermore, in the mouse
studies, the amount of the nanoparticle required to deliver
the paclitaxel was nontoxic to the mice (Fig. 2).
The mechanism of the drug sensitisation is not clear.
Possibly, the entrapment of the drug inside the nano-
particles shields it from the efflux transporters. In compar-
ison, when the free drug is absorbed by the cells, it is more
actively pumped out from the cell. The difference in this
gradient gives credence to particle-trafficking mechanisms
via structural engulfment rather than hypothesis of Fickian
diffusion across the intracellular and paracellular routes.
Also, since tubulin is one of the essential components of
the structural architecture of cell, there is a higher chance of
the bound paclitaxel to escape the efflux pump and
contribute to tubulin depletion within the cell. Furthermore,
due to the enhanced permeation and retention (EPR) effect
of the tumour environment (Maeda 1992), the particles are
expected to accumulate and produce a constantly available
supply of sheathed paclitaxel to the cancer cells.
The relative inferior efficacy of the nanoparticles
compared with the standard formulation of paclitaxel could
be explained by a difference in the oral uptake of the drug.
Rapidly multiplying cells generally exhibit higher sensitiv-
ity to a cytotoxic drug compared to those multiplying
slowly (Lopes et al. 1993). The absolute cell kill in that
case is proportional to the drug concentration presented
which shall be higher for the i.v. formulation compared to
the oral formulation. Slowly multiplying cells, on the
contrary, would require a sustained exposure of the drug,
which will be provided by a formulation that can protect the
drug from degradation.
5 Conclusion
The presented study provides an exciting strategy to improve
the sensitivity of drug-resistant cancers especially of those
for which resistance is mediated via over-expression of efflux
transporters. The results in tumour model in nude mice
demonstrate the possibility to deliver paclitaxel by oral route
and the prospect of such formulations in increasing response












































Fig. 2 The effect of paclitaxel and paclitaxel nanoparticles on the
growth of tumours of cell line 2780 AD when grown as xenografts in
mice. Mice were treated once tumours reached a mean diameter of
0.5 cm. Groups of six mice were either untreated (●) given paclitaxel
(dissolved in cremophor EL, ethanol, dextrose) intravenously (▼)
empty nanoparticles orally (■) or paclitaxel-loaded nanoparticles
orally (♦) on days 0, 2, and 4. Tumour volumes (A) and body weights
(B) are expressed relative to that on the day of treatment (day 0), and
results are the mean±SEM of six mice
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